GSK plc
GSK
Positions held
Your positionsGSK isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- GSK has a strong market position in the healthcare sector, leveraging its extensive portfolio of vaccines and pharmaceuticals to maintain competitive advantage.
- GSK's revenue increased by 10% in the latest quarter, reaching $8.4 billion compared to $7.6 billion in the prior quarter.
- The company has a market capitalization of approximately $93.36 billion, indicating significant investor confidence.
- GSK faces challenges with a declining earnings growth rate, which has decreased by 69.5% year-over-year.
- The operating margin has compressed significantly to 5.7%, down from 30.1% in the previous quarter.
- The stock has a 'Strong Sell' signal with a score of -32.00, indicating bearish market sentiment.
Fundamentals
| Market cap | $93.24B | Enterprise value | $107.96B | Trailing P/E | 14.68 | Forward P/E | 9.42 |
| PEG | 5.73 | Price / book | 3.96 | Beta | 0.28 | Dividend yield | 3.90% |
| Revenue growth | 5.3% | Earnings growth | -69.5% | Gross margin | 73.5% | Operating margin | 30.9% |
| Profit margin | 14.5% | ROE | 33.4% | ROA | 10.0% | Debt / equity | 1.06 |
| Current ratio | 0.82 | Free cash flow | $3.48B | Analyst recommendation | hold | Mean target | $59.33 |
| 52w high | $61.70 | 52w low | $42.85 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $8.4B | $7.6B | $8.6B | $8.5B | $8.0B | — |
| Op margin | 5.7% | 30.1% | 17.5% | 30.3% | 25.3% | — |
| Net income | $435M | $1.7B | $636M | $2.0B | $1.4B | — |
| Gross margin | 73.1% | 75.4% | 69.2% | 73.6% | 72.9% | — |
| Gross profit | $6.1B | $5.8B | $6.0B | $6.3B | $5.8B | — |
| Operating income | $481M | $2.3B | $1.5B | $2.6B | $2.0B | — |
- Revenue +10% vs prior quarter ($8.4B vs $7.6B).
- Gross margin 73% (was 75.4% prior quarter).
- Operating margin compressed to 5.7%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $32.7B | $31.4B | $30.3B | $29.3B | — |
| Op margin | 25.5% | 17.7% | 24.2% | 22.9% | — |
| Net income | $5.7B | $2.6B | $4.9B | $15.0B | — |
| Gross margin | 72.4% | 71.2% | 71.8% | 67.4% | — |
| Gross profit | $23.6B | $22.3B | $21.8B | $19.8B | — |
| Operating income | $8.3B | $5.5B | $7.3B | $6.7B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Viola Davis partners with GSK to educate adults 50 and older about their shingles risk
2026-10-08 · GSK (LSE:GSK) Deepens Its Drug Pipeline Through Two Research Partnerships
2026-10-07 · GSK (LSE:GSK) Stock May Trade Below Fair Value Despite Fresh Cabenuva Trial News
2026-10-05 · Cerebras Systems’ Tough 2026 Continues: It’ll Double Soon According to One of The Biggest Global Banks
2026-10-01 · Abbott Stock And Other Healthcare Dividend Names Built For Supply Chain Shocks
2026-09-30 · GSK (LSE:GSK) The Latest Update Raises A Bigger Question
2026-09-29 · GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?
2026-09-29 · GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated
2026-09-28 · Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
2026-09-24 · Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum
Price (daily)
Full chart · RSI · MACD · patterns